HQ

HealthEquity, Inc.

HQYHealthcareNASDAQ

Health Information Services

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$1.31B
+9.5% YoY
Net Income
$215.2M
+122.5% YoY
EBITDA
$489.2M
+44.3% YoY
Free Cash Flow
$397.5M

Scan Results

Daily timeframe
DateIndicatorDetails
Sep 1CONFIRMED RSI OversoldRSI 29.2, below 30, stock may be oversold
Aug 31CONFIRMED RSI OversoldRSI 27.1, below 30, stock may be oversold
About HealthEquity, Inc.

HealthEquity, Inc. provides technology-enabled services platforms to consumers and employers in the United States. At a $7.72B market cap, HealthEquity, Inc. ranks as a mid-cap company within healthcare. It offers health savings accounts (HAS); investment platform; online-only automated investment advisory services through Advisor, a Web-based tool.

Where HQY stands vs its 150-day and 200-day moving averages

As of the September 1, 2026 close, HQY finished 10.17% above its 150-day moving average ($87.63) and 7.94% above its 200-day moving average ($89.44). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is HQY overbought or oversold?

At the September 1, 2026 close, HQY's RSI(14) was 29.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$7.72B
P/E (TTM)33.70
Fwd P/E16.99
EPS$2.77
Beta0.23
52W Change+5.0%
ROE11.4%
Analysis

On the balance sheet, HQY has $256.0M in cash with $971.0M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $397.5M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 11.4% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 6.7% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $861.7M (2023) to $1.31B (2026), reflecting a 52% increase over the period.

With a beta below 0.7, HealthEquity, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for HealthEquity, Inc. and its sector.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms